Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Current Algorithms and Prognostic Factors in the Treatment of Metastatic Renal Cell Carcinoma

(2009) Ana M. Molina et al.   Clinical Genitourinary Cancer

Multitarget drugs: the present and the future of cancer therapy

(2009) Annalisa Petrelli et al.   EXPERT OPINION ON PHARMACOTHERAPY

Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

(2009) Richard T. Kloos et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of p38 MAP kinase pathway induces apoptosis and prevents Epstein Barr virus reactivation in Raji cells exposed to lytic cycle inducing compounds

(2009) Giulia Matusali et al.   Molecular Cancer

Use of rituximab in diffuse large B-cell lymphoma in the salvage setting

(2008) Christian Gisselbrecht   BRITISH JOURNAL OF HAEMATOLOGY

The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas

(2008) Jeremy S. Abramson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Mutations of the PIK3CA Gene in Diffuse Large B Cell Lymphoma

(2008) Yu Baohua et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

(2008) Weiguo Zhang et al.   JNCI-Journal of the National Cancer Institute

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway

(2008) W Zhang et al.   LEUKEMIA

Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas

(2008) F. Yang et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Metastatic Melanoma: Scientific Rationale for Sorafenib Treatment and Clinical Results

(2008) Friederike Egberts et al.   ONKOLOGIE